Ureteral Metastasis From Prostate Cancer: A Report of Two Cases
7 Dog Breeds Most Prone To Cancer: What Every Pet Parent Should Be Aware Of
WorldAnimalFoundation.Org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn More
It's a difficult reality to face, but just like humans, dogs can develop many of the same cancers. In fact, dogs are the only non-human species that can get prostate cancer. According to the National Cancer Institute, about 6 million new cancer diagnoses are made in dogs each year. This number could be even higher since not all pets receive regular medical care or an official cancer diagnosis.
The Veterinary Cancer Society estimates that 1 in 4 dogs will develop cancer at some point in their lives, and nearly 50% of dogs over the age of 10 will be affected by it. The good news is that half of all canine cancers are treatable when caught early, and ongoing research continues to improve treatment options.
With that in mind, let's take a look at 7 dog breeds that are most prone to cancer, so you can be better prepared and give your furry friend the extra care they need to help prevent this disease.
Common Cancer Types in DogsCancer in dogs can take many forms, affecting the blood, bones, or body tissues. Getting an accurate diagnosis is important to ensure the best treatment and prognosis. Here are some common types of cancer that affect dogs:
Poodles are energetic, smart, and come in three sizes, making them a great fit for any dog lover. However, Standard Poodles, in particular, have a higher risk of developing cancer. It's estimated that about 40% of Poodles may die from some form of cancer.
One type they are especially prone to is squamous cell carcinoma of the digit (SCDD), a cancer that affects the toes and can cause bone disease. According to AKCCHF, this aggressive cancer often recurs multiple times in affected dogs, especially in dark-colored Standard Poodles, while light-colored ones are rarely affected.
Cancer is a leading cause of death in older dogs, and since Poodles tend to live longer than many breeds, their risk of cancer increases as they age. Fortunately, many cancers can be treated by surgically removing tumors, and chemotherapy is another option for certain types. The key to managing cancer in Poodles is early detection, which can greatly improve the chances of successful treatment.
2. Bernese Mountain DogsBernese Mountain Dogs are big, beautiful, and incredibly lovable, especially as puppies. Unfortunately, this breed is prone to several serious health issues, including hip and elbow dysplasia, gastric torsion (bloat), and mast cell tumors. They are also sensitive to heat, so care must be taken to avoid heat stroke.
While their friendly nature makes them popular pets, Bernese Mountain Dogs have a higher risk of cancer, mobility problems, and other health conditions. Many Bernese may pass away at a younger age compared to other breeds, with cancer being a leading cause of death.
WebMD points out that reduced genetic diversity has contributed to declining health, but responsible owners can take steps to protect their pets' well-being. Sadly, their life expectancy, once 10 to 12 years, has now dropped to 7 to 10 years due to these growing medical concerns.
3. BeaglesOwning a Beagle is a joy, as they are friendly, playful, and easy to train due to their eagerness to please. These adorable and intelligent hunting dogs make great companions. However, Beagles can experience certain health issues, such as recurring urinary tract infections, and they are at a higher risk of developing bladder cancer, especially if they are exposed to lawn chemicals like pesticides and herbicides.
Beagles tend to live longer than many other breeds, which means they are more likely to develop cancer in their later years. Cancer is a leading cause of death in older pets, and Beagles are particularly prone to a type of cancer called lymphoma.
Fortunately, half of all cancers can be treated by surgical removal, and some can be managed with chemotherapy. Early detection is key to giving your Beagle the best chance at a long and happy life.
4. Golden RetrieversGolden Retrievers are adored for their playful and intelligent personalities, making them one of the best family pets. However, their popularity has unfortunately led to an increase in health problems, especially cancer. In fact, Golden Retrievers are now one of the most likely breeds to develop cancer, with around 65% of them passing away due to the disease.
Over the past 50 years, their lifespan has decreased as the risk of cancer and other health issues has dramatically risen, particularly in the United States. Recent studies have identified two genes linked to cancer in Golden Retrievers, which offers hope for future detection and prevention.
Their larger size and age also contribute to their higher risk of developing cancer. While responsible breeding can help reduce these issues, factors like diet, exposure to toxins, and lifestyle also play a significant role in cancer susceptibility. Keeping a close eye on your Golden's health and environment can go a long way in helping them live a long and happy life.
5. RottweilerRottweilers are large, powerful dogs, originally descended from Roman military dogs and developed in Germany, known for their strength and natural guardian instincts. Despite their tough exterior, Rottweilers are playful, loyal, and devoted to their families.
Unfortunately, Rottweilers are at a higher risk of developing several types of cancer, including lymphoma, mast cell tumors, soft tissue sarcomas, bone cancer, bladder cancer, and hemangiosarcomas. Lymphoma, or lymphosarcoma, is particularly common in Rottweilers. Purina Pro Club note that this cancer affects the lymphocytes, a type of white blood cell vital to the immune system.
Since white blood cells are found throughout the body, lymphoma can develop in multiple areas, making it a challenging cancer to detect and treat. Because of the breed's susceptibility, it's important to be vigilant for any potential signs of lymphoma and ensure regular veterinary check-ups for early detection and treatment.
6. Doberman PinschersThe Doberman Pinscher is a loyal and protective companion, known for its strong guarding instincts. Sadly, Dobermans are prone to several diseases that can significantly reduce their lifespan and impact their quality of life.
Health issues commonly affecting this breed include dilated cardiomyopathy, hepatitis, hypothyroidism, cervical vertebral instability, and numerous cancers. Research suggests that Dobermans may have a higher risk of developing cancer, with the breed often being overrepresented in cases of lymphoma, osteosarcoma, mammary cancer, and prostate cancer.
These health challenges make it crucial for Doberman owners to stay vigilant with regular veterinary care to catch and manage potential illnesses early.
7. German ShepherdsGerman Shepherds are highly intelligent and versatile dogs originally bred in Germany to guard and herd sheep. Today, they excel in various roles, from police work to being loyal companion animals. Unfortunately, this beloved breed also has a high rate of cancer, which can impact their lifespan, typically between 10 and 12 years.
Genetics are thought to play a role in the likelihood of developing cancer in German Shepherds. One of the most common cancers in German Shepherds is hemangiosarcoma, a malignant cancer affecting the circulatory system, often found in the heart or spleen.
This type of cancer is particularly dangerous because symptoms usually aren't noticeable until the tumor ruptures, leading to internal bleeding, collapse, or even death. To monitor your German Shepherd's health, it's a good idea to regularly check their gums—pale or white gums could be a sign of circulatory issues and warrant immediate veterinary attention.
ConclusionVarious dog breeds face an increased risk of developing canine cancer, with certain breeds more susceptible than others. For example, the Bernese Mountain Dog and other large and giant breeds are known to have a higher likelihood of developing conditions like mast cell tumors, liver cancer, and skin cancer. While purebred dogs are often more prone to dog cancer due to inherited genetic traits, even a mixed breed dog is not immune.
Female dogs are also at risk of specific cancers, such as mammary tumors, especially if they are not spayed. It's important to note that environmental factors can also play a role in a dog's health, potentially increasing their cancer risk.
The key to maintaining a dog's health and minimizing cancer risk is through regular check-ups, early detection, and understanding the breed-specific risks. Conditions like brain cancer, cancer of the blood vessels, and other forms can affect pedigree dogs just as much as others. Whether your pet is a mixed breed or purebred, knowing these risks can help protect them and ensure they live a healthy and happy life.
Pennsylvania Vet Offers World's Only CyberKnife Cancer Treatment For Cats And Dogs
A high-tech kind of radiation designed for people is also being used for dogs and cats with cancer. The only dedicated veterinary center providing this treatment is in Malvern, Pennsylvania.
CyberKnife technology has evolved and can be a quick and easier treatment for our four-legged friends.
Cleo, an 11-year-old sheltie, is visiting from Rochester, New York, to get treatments for a cancerous brain tumor that caused seizures.
Cleo is Lily Kegl's best friend. She's here in Malvern at the BluePearl Pet Hospital at the recommendation of her New York vet.
"They said surgery was possible, but based on where it was, it just wasn't the best," Kegl said.
Instead, Cleo is having CyberKnife treatments, a pinpointed kind of radiology that's also used on people.
"Really the name of the game in radiation is getting that dose of radiation to the tumor but sparing all the healthy structures around it," Dr. Siobhan Haney from BluePearl CyberKnife Cancer Center said.
Haney, a radiation oncologist at BluePearl, says she treats dogs and cats from all over the country.
"This is the only veterinary dedicated CyberKnife in the world," Haney said.
She says before the treatment the tumor is carefully mapped with an MRI and CT scan.
Before the procedure, Haney says Cleo gets some anesthesia and feels nothing during the radiation that kills the cancer cells.
"There's no knife, no knifing involved. The makers of CyberKnife were trying to draw an analogy between the precision of this type of radiation therapy and the precision with which a surgeon would use their scalpel," Haney said.
Haney says CyberKnife is a good alternative to surgery because it's non-invasive.
"It really allows an animal to get back to a good quality of life very quickly and also with minimal side effects," Haney said.
Kegl says Cleo has been a little tired but you'd never know she's had three cancer treatments as they're now ready to head home.
For people who don't have pet insurance, CyberKnife can cost more than $10,000 depending on the location of the tumor and how many treatments are involved.
More from CBS News
University of Pennsylvania suspends professor over comments on race
What to know about zinc poisoning in dogsPet Project
Man shot 3 times in back inside Philadelphia subway station, police say
Fog alert lifted in Philadelphia region; Helene bringing bands of rain
Eagles game time today and more to know as the Birds take on the Bucs
Stephanie StahlTranslation Of New Cancer Treatments From Pet Dogs To Humans
Hansen, K. & Khanna, C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer 40, 858–880 (2004).
Withrow, S. J. & Vail, D. M. Withrow & MacEwen's Small Animal Clinical Oncology 846 (Saunders Elsevier, St. Louis, 2007).
Klein, W. R. Et al. Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol. Immunother. 21, 133–140 (1986).
Antinoff, N. & Hahn, K. Ferret oncology: diseases, diagnostics, and therapeutics. Vet. Clin. North Am. Exot. Anim. Pract. 7, 579–625 (2004).
Nasir, L. & Reid, S. W. Bovine papillomaviral gene expression in equine sarcoid tumours. Virus Res. 61, 171–175 (1999).
Heinzerling, L. Et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 16, 35–48 (2005).
Seltenhammer, M. H. Et al. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. Pigment Cell Res. 17, 674–681 (2004).
Hershey, A. E., Dubielzig, R. R., Padilla, M. L. & Helfand, S. C. Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis. Vet. Pathol. 42, 805–811 (2005).
MacEwen, E. G., Patnaik, A. K., Harvey, H. J., Hayes, A. A. & Matus, R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 4, 397–402 (1986).
Weiden, P. L. Et al. Treatment of canine malignancies by 1200 R total body irradiation and autologous marrow grafts. Exp. Hematol. 3, 124–134 (1975).
Tsoi, M. S., Weiden, P. L. & Storb, R. Lymphocyte reactivity to autochthonous tumor cells in dogs with spontaneous malignancies. Cell Immunol. 13, 431–439 (1974).
Storb, R., Epstein, R. B., Ragde, H., Bryant, J. & Thomas, E. D. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 30, 805–811 (1967).
Crow, S. E. Et al. Chemoimmunotherapy for canine lymphosarcoma. Cancer 40, 2102–2108 (1977).
Benjamini, E. Et al. Tumor vaccines for immunotherapy of canine lymphosarcoma. Ann. NY Acad. Sci. 277, 305–312 (1976).
Porrello, A., Cardelli, P. & Spugnini, E. P. Oncology of companion animals as a model for humans. An overview of tumor histotypes. J. Exp. Clin. Cancer Res. 25, 97–105 (2006).
Mueller, F., Fuchs, B. & Kaser-Hotz, B. Comparative biology of human and canine osteosarcoma. Anticancer Res. 27, 155–164 (2007).
Waters, D. J. & Wildasin, K. Cancer clues from pet dogs. Sci. Am. 295, 94–101 (2006).
Waters, D. J. High-grade prostatic intraepithelial neoplasia in dogs. Eur. Urol. 35, 456–458 (1999).
Knapp, D. W. & Waters, D. J. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol. Med. Today 3, 8–11 (1997).
Khanna, C. Et al. The dog as a cancer model. Nature Biotechnol. 24, 1065–1066 (2006).
Lindblad-Toh, K. Et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438, 803–819 (2005).
Ostrander, E. A., Giger, U. & Lindblad-Toh, K. The Dog and its Genome 584 (Cold Spring Harbor Laboratory, New York, 2006).
Thomas, R. Et al. Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res. 15, 1831–1837 (2005).
Withrow, S. J., Powers, B. E., Straw, R. C. & Wilkins, R. M. Comparative aspects of osteosarcoma. Dog versus man. Clin. Orthop. Relat Res. 270, 159–168 (1991).
Vail, D. M. & MacEwen, E. G., Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 18, 781–792 (2000).
O'Brien, S. J. & Murphy, W. J. Genomics. A dog's breakfast? Science 301, 1854–1855 (2003).
Hoffman, M. M. & Birney, E. Estimating the neutral rate of nucleotide substitution using introns. Mol. Biol. Evol. 24, 522–531 (2007).
Patronek, G. J., Waters, D. J. & Glickman, L. T. Comparative longevity of pet dogs and humans: implications for gerontology research. J. Gerontol A Biol. Sci. Med. Sci. 52, B171–B178 (1997).
Bukowski, J. A., Wartenberg, D. & Goldschmidt, M. Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. J. Toxicol. Environ. Health A 54, 579–591 (1998).
Hayes, H. M., Jr & Fraumeni, J. F., Jr. Epidemiological features of canine renal neoplasms. Cancer Res. 37, 2553–2556 (1977).
Misdorp, W. & Hart, A. A. Canine mammary cancer. II. Therapy and causes of death. J. Small Anim. Pract 20, 395–404 (1979).
Mukaratirwa, S. Prognostic and predictive markers in canine tumours: rationale and relevance. A review. Vet. Q. 27, 52–64 (2005).
Olson, P. N. Using the canine genome to cure cancer and other diseases. Theriogenology 68, 378–381 (2007).
Thomas, R., Smith, K. C., Ostrander, E. A., Galibert, F. & Breen, M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br. J. Cancer 89, 1530–1537 (2003).
Khanna, C. Et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin. Cancer Res. 8, 2406–2412 (2002).
Khanna, C. & Vail, D. M. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr. Cancer Drug Targets 3, 265–273 (2003).
Bergman, P. J. Et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin. Cancer Res. 9, 1284–1290 (2003).
Mutsaers, A. J., Widmer, W. R. & Knapp, D. W. Canine transitional cell carcinoma. J. Vet. Intern. Med. 17, 136–144 (2003).
Mohammed, S. I. Et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62, 356–358 (2002).
Koenig, A., Bianco, S. R., Fosmire, S., Wojcieszyn, J. & Modiano, J. F. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet. Pathol. 39, 458–472 (2002).
Modiano, J. F., Ritt, M. G. & Wojcieszyn, J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J. Vet. Intern. Med. 13, 163–174 (1999).
Setoguchi, A. Et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am. J. Vet. Res. 62, 433–439 (2001).
Haga, S. Et al. Overexpression of the p53 gene product in canine mammary tumors. Oncol. Rep. 8, 1215–1219 (2001).
Pryer, N. K. Et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin. Cancer Res. 9, 5729–5734 (2003).
Ozaki, K., Yamagami, T., Nomura, K. & Narama, I. Mast cell tumors of the gastrointestinal tract in 39 dogs. Vet. Pathol. 39, 557–564 (2002).
London, C. A., Kisseberth, W. C., Galli, S. J., Geissler, E. N. & Helfand, S. C. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J. Comp. Pathol. 115, 399–414 (1996).
London, C. A. Et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27, 689–697 (1999).
Kiupel, M., Webster, J. D., Kaneene, J. B., Miller, R. & Yuzbasiyan-Gurkan, V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet. Pathol. 41, 371–377 (2004).
Anderson, P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2, 333–343 (2006).
Leahy, M. F., Seymour, J. F., Hicks, R. J. & Turner, J. H. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 24, 4418–4425 (2006).
Tomita, N. Et al. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma. Leuk. Lymphoma 47, 1041–1047 (2006).
Rusk, A. Et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin. Cancer Res. 12, 7456–7464 (2006).
MacDonald, V. S., Thamm, D. H., Kurzman, I. D., Turek, M. M. & Vail, D. M. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J. Vet. Intern. Med. 19, 732–736 (2005).
Avery, A. C. & Avery, P. R. Determining the significance of persistent lymphocytosis. Vet. Clin. North Am. Small Anim. Pract. 37, 267–282 (2007).
Lana, S., Plaza, S., Hampe, K., Burnett, R. & Avery, A. C. Diagnosis of mediastinal masses in dogs by flow cytometry. J. Vet. Intern. Med. 20, 1161–1165 (2006).
Lana, S. E., Jackson, T. L., Burnett, R. C., Morley, P. S. & Avery, A. C. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J. Vet. Intern. Med. 20, 329–334 (2006).
Forrest, L. J. Et al. The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. Int. J. Radiat. Oncol. Biol. Phys. 60, 1639–1644 (2004).
Kippenes, H. Et al. Spatial accuracy of fractionated IMRT delivery studies in canine paraspinal irradiation. Vet. Radiol Ultrasound. 44, 360–366 (2003).
Mackie, T. R. Et al. Image guidance for precise conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56, 89–105 (2003).
Rassnick, K. M. Et al. Treatment of canine mast cell tumors with CCNU (lomustine). J. Vet. Intern. Med. 13, 601–605 (1999).
Ogilvie, G. K. Et al. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987–1991). J. Am. Vet. Med. Assoc. 202, 304–306 (1993).
Ogilvie, G. K. Et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J. Am. Vet. Med. Assoc. 195, 1584–1587 (1989).
Bergman, P. J. Et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J. Vet. Intern. Med. 10, 76–81 (1996).
Garrett, L. D., Thamm, D. H., Chun, R., Dudley, R. & Vail, D. M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 16, 704–709 (2002).
Kamb, A., Wee, S. & Lengauer, C. Why is cancer drug discovery so difficult? Nature Rev. Drug Discov. 6, 115–120 (2007).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
LaRue, S. M. Et al. Limb-sparing treatment for osteosarcoma in dogs. J. Am. Vet. Med. Assoc. 195, 1734–1744 (1989).
Withrow, S. J. Et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71, 2484–2490 (1993).
Dewhirst, M. W. Animal modeling and thermal dose. Radiol. Clin. North Am. 27, 509–518 (1989).
Dow, S. W. Et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Invest. 101, 2406–2414 (1998).
Dow, S. W. & Potter, T. A. Expression of bacterial superantigen genes in mice induces localized mononuclear cell inflammatory responses. J. Clin. Invest. 99, 2616–2624 (1997).
Elmslie, R. E. & Dow, S. W. Genetic immunotherapy for cancer. Semin. Vet. Med. Surg. (Small Anim.) 12, 193–205 (1997).
Ladiges, W. C. Et al. Failure of anti-MHC antibodies to prevent GVHD in DLA mismatched unrelated canine marrow recipients. Bone Marrow Transplant. 5, 43–46 (1990).
Ladiges, W. C., Storb, R. & Thomas, E. D. Canine models of bone marrow transplantation. Lab. Anim. Sci. 40, 11–15 (1990).
Whelan, H. T. Et al. The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. J. Neurosurg. 79, 562–568 (1993).
Hershey, A. E. Et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. 5, 2653–2659 (1999).
Khanna, C. Et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 49, 960–971 (1997).
Khanna, C. Et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79, 1409–1421 (1997).
Khanna, C., Hasz, D. E., Klausner, J. S. & Anderson, P. M. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin. Cancer Res. 2, 721–734 (1996).
Otterson, G. A. Et al. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin. Cancer Res. 13, 1246–1252 (2007).
Rao, R. D., Anderson, P. M., Arndt, C. A., Wettstein, P. J. & Markovic, S. N. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am. J. Clin. Oncol. 26, 493–498 (2003).
Rao, R. D., Markovic, S. N. & Anderson, P. M. Aerosol therapy for malignancy involving the lungs. Curr. Cancer Drug Targets. 3, 239–250 (2003).
Rusk, A. Et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin. Cancer Res. 12, 7444–7455 (2006).
London, C. A. Et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 9, 2755–2768 (2003).
Zemke, D., Yamini, B. & Yuzbasiyan-Gurkan, V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet. Pathol. 39, 529–535 (2002).
Reguera, M. J., Rabanal, R. M., Puigdemont, A. & Ferrer, L. Canine mast cell tumors express stem cell factor receptor. Am. J. Dermatopathol 22, 49–54 (2000).
Anderson, P. M. Et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5, 2316–2323 (1999).
Norden-Zfoni, A. Et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13, 2643–2650 (2007).
Britten, C. D. Et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 61, 515–524 (2007).
Figlin, R. A. Newly approved therapies for RCC and their effect on the standard of care. Clin. Adv. Hematol. Oncol. 5, 35–36, 66 (2007).
Hornick, J. L. & Fletcher, C. D. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum. Pathol. 38, 679–687 (2007).
Rubin, B. P., Heinrich, M. C. & Corless, C. L. Gastrointestinal stromal tumour. Lancet 369, 1731–1741 (2007).
von Mehren, M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin. Colorectal Cancer 6 (Suppl. 1), S30–S34 (2006).
Kurzman, I. D. Et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res. 1, 1595–1601 (1995).
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S. & Jaffe, N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18, 93–99 (1995).
Kleinerman, E. S. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol. Oncol. Clin. North Am. 9, 927–938 (1995).
Meyers, P. A. Et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23, 2004–2011 (2005).
Nardin, A., Lefebvre, M. L., Labroquere, K., Faure, O. & Abastado, J. P. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 6, 123–133 (2006).
Liao, J. C. Et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6, 8 (2006).
Bergman, P. J. Et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24, 4582–4585 (2006).
MacEwen, E. G., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 5, 4249–4258 (1999).
Vail, D. M. Et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin. Cancer Res. 1, 1165–1170 (1995).
Mack, G. S. Clinical trials going to the dogs: canine program to study tumor treatment, biology. J. Natl Cancer Inst. 98, 161–162 (2006).
Martirosov, K. S., Grigor'ev Iu, G., Borovkov, M. V. & Zorin, V. V. [Experimental study of the role of blocking 5-HT3-receptors of serotonin and D2-receptors of dopamine in the mechanism of early radiation vomiting in dogs]. Radiats Biol. Radioecol 42, 75–79 (2002) (in Russian).
Legeza, V. I., Shagoian, M. G., Kamynina, M. F., Markovskaia, I. V. & Martirosov, K. S. [Mechanism of the species characteristics of the sensitivity of monkeys and dogs to the emetic action of various pharmacological agents]. Biull Eksp. Biol. Med. 93, 64–66 (1982) (in Russian).
Modiano, J. F. Et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 65, 5654–5661 (2005).
Lingaas, F. Et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum. Mol. Genet. 12, 3043–3053 (2003).
MacEwen, E. G., et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J. Drug Target 2, 391–396 (1994).
Thamm, D. H. Et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin. Cancer Res. 11, 4827–4834 (2005).
Mack, G. S. Cancer researchers usher in dog days of medicine. Nature Med. 11, 1018 (2005).
Reiser, H. Et al. GS-9219 - A novel acyclic nucleotide analog with potent anti-neoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin. Cancer Res. (in the press).
Comments
Post a Comment